Assessment of the conjunctival microcirculation for patients presenting with acute myocardial infarction compared to healthy controls by Brennan, Paul F. et al.
                                                                    
University of Dundee
Assessment of the conjunctival microcirculation for patients presenting with acute
myocardial infarction compared to healthy controls









Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Brennan, P. F., McNeil, A. J., Jing, M., Awuah, A., Moore, J. S., Mailey, J., Finlay, D. D., Blighe, K., McLaughlin,
J. A. D., Nesbit, M. A., Trucco, E., Moore, T. C. B., & Spence, M. S. (2021). Assessment of the conjunctival
microcirculation for patients presenting with acute myocardial infarction compared to healthy controls. Scientific
Reports, 11(1), [7660]. https://doi.org/10.1038/s41598-021-87315-7
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. May. 2021
1
Vol.:(0123456789)
Scientific Reports |         (2021) 11:7660  | https://doi.org/10.1038/s41598-021-87315-7
www.nature.com/scientificreports
Assessment of the conjunctival 
microcirculation for patients 
presenting with acute myocardial 
infarction compared to healthy 
controls
Paul F. Brennan1,2*, Andrew J. McNeil2, Min Jing4, Agnes Awuah2, Julie S. Moore2, 
Jonathan Mailey1, Dewar D. Finlay4, Kevin Blighe2, James A. D. McLaughlin4, 
M. Andrew Nesbit2, Emanuele Trucco3, Tara C. B. Moore2 & Mark S. Spence1 
Microcirculatory dysfunction occurs early in cardiovascular disease (CVD) development. Acute 
myocardial infarction (MI) is a late consequence of CVD. The conjunctival microcirculation is readily-
accessible for quantitative assessment and has not previously been studied in MI patients. We 
compared the conjunctival microcirculation of acute MI patients and age/sex-matched healthy 
controls to determine if there were differences in microcirculatory parameters. We acquired images 
using an iPhone 6s and slit-lamp biomicroscope. Parameters measured included diameter, axial 
velocity, wall shear rate and blood volume flow. Results are for all vessels as they were not sub-
classified into arterioles or venules. The conjunctival microcirculation was assessed in 56 controls 
and 59 inpatients with a presenting diagnosis of MI. Mean vessel diameter for the controls was 
21.41 ± 7.57 μm compared to 22.32 ± 7.66 μm for the MI patients (p < 0.001). Axial velocity for the 
controls was 0.53 ± 0.15 mm/s compared to 0.49 ± 0.17 mm/s for the MI patients (p < 0.001). Wall shear 
rate was higher for controls than MI patients (162 ± 93  s−1 vs 145 ± 88  s−1, p < 0.001). Blood volume flow 
did not differ significantly for the controls and MI patients (153 ± 124 pl/s vs 154 ± 125 pl/s, p = 0.84). 
This pilot iPhone and slit-lamp assessment of the conjunctival microcirculation found lower axial 
velocity and wall shear rate in patients with acute MI. Further study is required to correlate these 
findings further and assess long-term outcomes in this patient group with a severe CVD phenotype.
Globally cardiovascular disease (CVD) is a leading cause of morbidity and mortality with an estimated 17.7 mil-
lion people dying from CVD each  year1. CVD also represents a substantial economic burden and in Northern 
Ireland alone, it is estimated that around £400 million per year is spent on  CVD2. Cardiovascular screening and 
primary prevention are important elements of the healthcare system. CVD risk models such as the Q-Risk 3 
score provide a 10-year estimate of the likelihood of a patient sustaining a major adverse cardiovascular event 
(MACE) occurring e.g. myocardial infarction (MI), cerebrovascular accident (CVA)3,4.
Microcirculatory dysfunction represents the earliest stages of  CVD5. Microvascular networks that are readily-
accessible for evaluation include the retinal circulation, sublingual circulation and nail-fold  circulation6–8. The 
conjunctival microcirculation gains its blood supply from the anterior ciliary branch of the ophthalmic  artery9. 
Conjunctival microcirculatory parameters, namely diameter (D), axial velocity (Va), blood volume flow (Q)
and wall shear rate/stress (WSR/WSS) have previously been assessed using a non-invasive combination of a 
slit-lamp biomicroscope and digital charge-coupled device (CCD)  camera10–16. The study of the conjunctival 
microcirculation, using these methods, has been applied to patients at high CVD-risk e.g. post CVA, diabetic 
 retinopathy17,18. Correlation between conjunctival microcirculatory abnormalities and CVD risk calculation, 
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using the Framingham Risk Score has also been  reported19,20. Haemoglobin video imaging (HVI) has recently 
been described for assessing the branching patterns within the conjunctival  circulation21.
Assessment of the conjunctival microcirculation in patients with acute MI, has not been described. A prior 
rabbit  model22, however, demonstrated a relationship between conjunctival venous diameter velocity, blood 
volume flow and the administration of either the potent vasoconstrictor alpha-adrenergic agonist phenylephrine 
or the negatively inotropic beta-adrenergic blocker esmolol. Nail-fold capillary diameters have been shown to 
be more dilated in patients with chronic heart failure (CHF) compared to  controls23. These responses of the 
microcirculation to alterations in vasoreactivity, cardiac inotropy and heart failure status could all potentially 
be encountered in patients with acute MI.
We recently reported the feasibility of assessing the conjunctival microcirculation using an iPhone 6s (Apple, 
USA) and slit-lamp biomicroscope in a group of low CVD-risk  controls24. The purpose of this study was to quan-
tifiably assess the conjunctival microcirculation of patients that had recently suffered an acute type 1 MI, based 
on the 4th universal definition of MI compared to a group of age- and sex-matched  controls25.
Methods
Study design. We conducted a prospective study (Integrated Research Application System study number 
166742) of inpatients who had suffered a recent myocardial infarction compared to a group of low CVD risk 
controls at the Royal Victoria Hospital, Belfast, United Kingdom. All subjects were screened and provided with 
verbal and written information and consented prior to study enrolment. Informed consent was obtained from 
all participants. Participants were recruited to the study in accordance with the Declaration of Helsinki. The 
experimental protocol was approved by the Research Ethics committee in the Belfast Health and Social Care 
Trust (BHSCT) and Ulster University (UU).
Criteria for the MI patients included that they were currently an inpatient with acute type 1 MI, not pregnant 
and greater than 17 years age. Key inclusion criteria for the control patients was that they were of low CVD risk 
and did not have prior history of coronary artery disease, MI, stroke, diabetes or uncontrolled systemic hyper-
tension. Exclusion criteria for both groups included inability to consent, a history of recent conjunctival inflam-
mation, prior refractive surgery, use of ocular medications (excluding artificial tears) and current use of contact 
lenses. In addition to the exclusion screening questionnaire all patients were examined by a clinical optometrist 
at the time of conjunctival imaging to assess for active signs of inflammation or dry eyes.
Baseline characteristics and quantitative conjunctival microcirculatory parameters were compared between 
both patient groups. The Q-Risk 3 score was calculated to estimate the 10-year risk of MACE for the control 
group.
The definitions of ST elevation and Non-ST elevation MI (STEMI, NSTEMI) were as described in the respec-
tive European Society of Cardiology  guidelines26,27.
Baseline clinical data and characteristics were obtained using the recruitment questionnaire, the inpatient 
clinical notes (if an acute MI patient), the hospital cardiology database (Cardiovascular Information System 
Tomcat, Phillips, Eindhoven, Netherlands) and the patient’s Northern Ireland Electronic Care Record (NIECR). 
Long-term clinical outcomes were determined using NIECR.
Conjunctival assessment. Conjunctival microcirculation image acquisition for both eyes was performed 
under the same settings for all patients. Using our previously reported  methods24 we acquired images using a 
Topcon SL-D4 (Topcon Medical Systems Inc., USA), an iPhone 6s smartphone (Apple, Inc, USA) and a bespoke 
adapter (Zarf Enterprises Inc., USA) as illustrated in Fig. 1. The optimal configuration was set at a resolution of 
1920 × 1080 pixels, captured at 60 frames per second. Using the third-party application “ProMovie Recorder” 
(http:// www. promo vieapp. com) we locked the video zoom setting at magnification 2×, providing a 1:1- pixel 
mapping of the camera sensor at 1080 pixel resolution. We acquired 5–10 s videos of the conjunctival micro-
Figure 1.  The iPhone 6s, TopCon SL-D4 imaging system with the Zarf bespoke adapter (red arrow) and 
TopCon external fixation target (green arrow).
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circulation medial and lateral to the iris, this generating four videos per subject. An external fixation target was 
used to minimise blinking and eye motion. A processed stabilised video of the left nasal conjunctival microcir-
culation is provided in Supplementary Video file 1.
We quantifiably assessed diameter (D), axial velocity (Va), blood volume flow (Q) and wall shear rate (WSR) 
in vessels with observable flow.
MALTAB R2019b (MathWork, USA) was used for programming. The sharpest frame in the sequence was 
automatically selected as a reference frame and all other frames registered to it. The Matlab function imregister.m 
was used for automatic registration. Automatic vessel filtering was implemented using Matlab code available 
 in28 Vessel centreline extraction and branch/end-point detection was automatically applied to the image using 
Matlab function bwmorph.m.
The Euclidean Distance Transform (EDT) principle was used to calculate vessel diameter (D). The value at 
each pixel of EDT map was automatically calculated based on the Euclidean distance between the pixel and its 
nearest nonzero pixel in the binary vessel image. The vessel centreline was used to obtain the central EDT values 
and radius along the vessel axis. The final vessel diameter estimation is provided by averaging the diameters 
found along the length of the vessel.
Axial velocity was estimated based on the spatial–temporal image (STI) obtained from the vessel segment and 
continuous wavelet transform (CWT) method, with the change in STI intensity reflecting erythrocyte movement 
through the vessel. The (CWT) has been applied as a spatio-temporal filter for motion capture for 1-dimension 
plus time (1D + T)  signals29–31. The STI is a time sequence signal denoted as I(x,t), where each value in the image 
represents the intensity at the position x in the corresponding vessel centreline and time point t. The change 
in STI intensity reveals the blood flowing through the vessel within the given time (or video frames) and as 
described previously this was performed semi-automatically24.
The blood volume flow rate (Q) was automatically calculated based on the principles defined in previous 
 works11,24 by the product of the cross-sectional velocity Vs  and the cross-sectional area (assuming a circular 
cross-section (1)):
The wall shear rate (WSR) was calculated by dividing the cross-sectional velocity by the diameter as evidenced 
in (2)
For microvessel diameters less than approximately 20 μm, a velocity profile cannot be used in the ordinary 
sense in order to estimate  Vs32. Therefore,  Vs  is obtained based on a profile factor function that has been pre-
viously described in other  work33, in which the relationship between the cross-sectional velocity Vs and axial 
velocity Va is represented as:
where Dc is the size of the average human erythrocyte diameter that is 7.65 μm as described  in33.
Figure 2 is a flow-chart illustrating the processing stages.
Methodology repeatability was assessed by one observer analysing the video sequences for 5 control sub-
jects twice, blinded to the clinical and demographic details of each subject. The repeated measurements were 
obtained from 38 vessel segments (5–9 per subject) and sample size was similar to other well-established con-
junctival analysis  work16. Differences in the four main measured parameters (D, Va, Q, WSR) were compared. 
Coefficients of repeatability (CR) were calculated using conventional  approaches33. The mean difference for D 
was − 0.01 ± 0.04 μm, CR 0.08 μm (95%CI − 0.09 μm to 0.07 μm) and for Va was 0.002 mm/s ± 0.01 mm/s, CR 
0.02 mm/s (95%CI − 0.02 mm/s to 0.02 mm/s). The mean difference for Q was 0.03 ± 2.14 pl/s, CR 4.19 pl/s 
(95%CI − 4.1 pl/s to 4.2 pl/s) and for WSR was 0.78 ± 4.17  s−1, CR 8.18  s−1 (95%CI − 7.4 to 9.0  s−1). These results 
















) , when D/Dc > 0.6.
Figure 2.  Flow-chart illustrating the individual processing stages from image registration to results output. 
Each step is labelled as automatic (A), manual (M) or semiautomatic (SA).
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To overcome the heterogenous anatomical properties of the conjunctival microcirculation we applied a vessel 
grouping classification to our results based on vessel diameter i.e. group 1 (D < 11 μm), group 2 (D 11–16 μm), 
group 3 (D 16–22 μm) and group 4 (D > 22 μm)10,24. Vessels were not separated into venules or arterioles and 
results are provided for all vessels.
Statistical analysis. For statistical analysis SPSS for Apple iOS version 25 (property of IBM) was used. 
Continuous variables were described using the mean, standard deviation of the mean and 95% confidence 
intervals (CI). The median was applied if the continuous variable was not normally distributed. Kolmogorov–
Smirnov testing was used to assess normality of the continuous variables. Categorical variables were expressed 
as a number and percentage of the total category number to which the variable belonged.
Normally distributed variables were compared between the two populations using the independent-sam-
ples t-test. Non-normally distributed continuous variables were compared using non-parametric tests e.g. 
Mann–Whitney U test. Categorical comparisons were made between the two groups using Pearson Chi-Square 
or Fisher’s exact test.
A one-way analysis of variance (ANOVA) was used to compare differences between the two groups based on 
the vessel group classifications and the fields of view imaged, followed by post-hoc testing where indicated to 
assess the origin of the statistical significance. Bonferroni post-hoc testing was applied if normal variance was 
assumed and Games-Howell if normal variance could not be assumed.
An α-level of less than 0.05 was determined to be of statistical significance. As this was an exploratory pilot 
study a formal power calculation was not performed. Results are described based on the number of vessel seg-
ments. A total of 4163 vessel segments were analysed and reported in the results section (controls 1904 total, 34 
per patient vs MI 2259 total, 38 per patient) providing a large number of vessels for comparison. The parameters 
for each study group from all vessel segments across the four videos were averaged for each patient prior to 
overall analysis. When vessel groups were compared (1–4), however, each parameter was averaged for all vessel 
segments falling within that vessel group.
Results
Baseline characteristics. Between the 31st January 2018 and 15th March 2019, 115 patients were recruited 
to this study. 48.7% (56/115) patients were healthy controls and 51.3% (59/115) were patients post-acute MI. 
The mean age for the control population was 53 ± 10 years compared to 57 ± 12 years for the acute MI patients 
(p = 0.07). 68% (38/56) the control population were male compared to 80% (47/59) of the acute MI patients 
(p = 0.15). The MI patients had a higher proportion of diabetes mellitus, systemic hypertension and smoking. 
The baseline Q-Risk 3 score for the controls was 8.1 ± 7.6%. Baseline characteristics are summarised in Table 1.
At the time of recruitment both groups were normotensive, with the control population having a significantly 
higher systolic (129 ± 16 mmHg vs. 121 ± 17 mmHg, p = 0.01) blood pressure and higher diastolic (77 ± 10 mmHg 
vs. 74 ± 11 mmHg, p = 0.10) blood pressure, but this did not reach statistical significance. This is explained by 
the appropriate administration of blood pressure (BP)-lowering medications, either newly started or long-term, 
for 95% of the MI population at the time of recruitment and patient medications are summarised in Table 2.
Within the MI group 21 (36%) had STEMI and 38 (64%) NSTEMI. There were no differences in mean age or 
sex of either MI group. The median time to recruitment post MI event was 1 day (interquartile range IQR 1–3, 
overall range day 0–22). 81% patients were recruited within 3 days of their MI, 91.5% within the first week and 
98.3% within 2 weeks. 49 (83%) of the MI patients had percutaneous coronary intervention (PCI), 6 (10%) had 
Table 1.  Summary of baseline characteristics for the healthy control and acute MI populations. Bold values 
are statistically significant (p < 0.05). IHD ischaemic heart disease, MI myocardial infarction, COPD chronic 
obstructive pulmonary disease.
Baseline characteristic Control (n = 56) MI (n = 59) p value
Age, years ± SD 53 ± 10 57 ± 12 0.07
Male sex n (%) 38 (68) 47 (80) 0.15
Q-Risk 3 score ± SD (%) 8.1 ± 7.6 Not applicable
Clinical IHD n (%) 0 11 (18.6)  < 0.001
Prior MI n (%) 0 8 (13.6) 0.006
Prior stroke n (%) 0 1 (1.7) 1
Hypertension n (%) 7 (12.5) 21 (35.6) 0.004
Diabetes mellitus n (%) 0 12 (20.3) 0.002
Dyslipidaemia n (%) 11 (19.6) 25 (42.4) 0.009
Smoking history n (%) 21 (37.5) 36 (61) 0.01
COPD n (%) 4 (7.1) 2 (3.4) 0.43
Creatine clearance, ml/min ± SD 84 ± 29 91 ± 37 0.56
Haemoglobin, g/l ± SD 146 ± 11 142 ± 15 0.08
Haematocrit, l/l ± SD 0.43 ± .03 0.42 ± .04 0.29
Platelet count,  10x9/l ± SD 263 ± 43 259 ± 64 0.27
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coronary artery bypass grafts (CABG) and 4 (7%) patients were medically managed without coronary revasculari-
sation. 28 (47%) of MI patients were recruited prior to coronary revascularisation with the remaining 31 (53%) 
of MI patients recruited after revascularisation. The breakdown of STEMI, in order of most to least frequent and 
based on the presenting electrocardiogram’s (ECG) suggested territory of infarction, was 47.7% (n = 10) inferior, 
33.3% (n = 7) anterior, 9.5% (n = 2) lateral and 9.5% (n = 2) posterior/inferolateral.
Left ventricular systolic dysfunction, based on a left ventricular ejection fraction < 50%, was observed in 
46% (n = 27) MI patients on their pre-discharge transthoracic echocardiogram (TTE). 8.5% (n = 5) patients had 
severe left ventricular systolic dysfunction (ejection fraction < 35%) on TTE. There was no in-hospital mortal-
ity, further MI or stroke. No patients had an implantable cardioverting defibrillator (ICD) or permanent pace-
maker (PPM) implanted. The STEMI group had a statistically higher TnThs compared to the NSTEMI group 
(3645 ± 3438 mmol/l vs. 527 ± 1077 mmol/l, p = 0.001) but creatinine clearance, Nt-proBNP and baseline lipid 
profiles did not differ, significantly, between the two groups. Baseline comorbidities were similar between the 
STEMI and NSTEMI group and are summarised in Table 3.
STEMI patients had a shorter total admission duration than NSTEMI patients (4.2 ± 3 days vs. 9.2 ± 13 days, 
p = 0.17). STEMI patients were treated via our regional primary PCI pathway with immediate revascularisation 
whereas the mean time to NSTEMI patient revascularisation was 5.6 ± 7 days. The mean time for NSTEMI 
patients to revascularisation with PCI was 2 ± 2 days compared to 18 ± 8 days for CABG (p < 0.001) and the 
PCI patients also had significantly shorter stays post revascularisation (2.3 ± 3 days vs. 13 ± 12 days, p < 0.001).
Repeat revascularisation occurred in 17% (n = 10) patients during a median follow-up of 361 days. The major-
ity of repeat revascularisation was planned (70%, n = 7). Unplanned revascularisation occurred in 30% (n = 3) 
of the MI repeat revascularisation group. Culprit vessel revascularisation occurred in 30% (n = 3) of this group. 
There were no cases of stent thrombosis during follow-up.
Only one patient was readmitted with HF presentation within 1 year. There was no cardiac mortality during 
follow-up. One MI patient died of lung adenocarcinoma (diagnosed after recruitment) during follow-up.
Table 2.  Pharmacological therapy at the time of recruitment. Bold values are statistically significant (p < 0.05).
Medication Control population (n = 56) MI population (n = 59) p value
Aspirin, n (%) 5 (8.9) 58 (98.3)  < 0.001
Ticagrelor, n (%) 0 52 (88.1)  < 0.001
Clopidogrel, n (%) 0 2 (3.4) 0.50
Prasugrel, n (%) 0 0 n/a
ACE inhibitors, n (%) 5 (8.9) 41 (69.5)  < 0.001
Angiotensin receptor blockers, n (%) 1 (1.8) 7 (11.9) 0.10
Mineralocorticoid antagonists, n (%) 0 11 (18.7) 0.003
Beta-blockers, n (%) 3 (5.4) 53 (89.8)  < 0.001
Any BP-lowering medication, n (%) 7 (12.5) 56 (95)  < 0.001
Statins, n (%) 8 (14.3) 55 (93.2)  < 0.001
Table 3.  Baseline characteristics and biomarkers for the STEMI and NSTEMI populations. SD standard 
deviation, STEMI ST segment elevation myocardial infarction, NSTEMI non ST segment elevation myocardial 
infarction, TnThs high-sensitivity troponin T, NT-proBNP N terminal pro brain natriuretic peptide, LDL low 
density lipoprotein, HDL high density lipoprotein, HbA1c glycated haemoglobin, LVEF left ventricular ejection 
fraction, IQR interquartile range.
Baseline characteristic STEMI (n = 21) NSTEMI (n = 38) p value
Age, years ± SD 55 ± 13 59 ± 11 0.20
Male sex, n (%) 17 (81) 30 (79) 1
Creatine clearance, ml/min ± SD 99 ± 50 89 ± 24 0.41
Diabetes mellitus, n (%) 2 (9.5) 10 (26.3) 0.18
Hypertension, n (%) 5 (23.8) 16 (42) 0.25
LVEF < 50%, n (%) 12 (57) 15 (38.5) 0.42
TnThs, mmol/l ± SD 3645 ± 3438 527 ± 1077 0.001
NT-proBNP, ng/L ± SD 1288 ± 1377 825 ± 1190 0.22
LDL, mmol/l ± SD 3.2 ± 1.7 2.6 ± 1.3 0.16
Cholesterol/HDL ratio ± SD 4.2 ± 0.4 4.2 ± 1.6 0.83
HbA1c, mmol/l ± SD 41 ± 5 49 ± 17 0.09
Time in hospital, days (IQR) 4 (2–6.5) 9 (2–10.5) 0.17
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Conjunctival analysis. Conjunctival microvascular videos were captured for all 115 patients. There were 
no reported complications or adverse outcomes associated with image acquisition. Processing of images and 
subsequent microvascular quantitative assessment was performed in an independent laboratory, blinded to the 
patient baseline characteristics and history to avoid bias.
A total of 4163 (control 1904 total, 34 per patient vs. MI 2259 total, 38 per patient) vessel segments were 
analysed for the two populations, with no significant differences in the mean number of vessel segments analysed 
per patient group (p > 0.05).
The mean vessel diameter for the controls was 21.41 ± 7.57 μm (95% CI 21.08–21.76 μm) which was signifi-
cantly lower than the 22.32 ± 7.66 μm (95% CI 22–22.64 μm) for the MI patients (p < 0.001). The mean axial 
velocity (Va) for the MI population was 0.49 ± 0.17 mm/s (95% CI 0.49–0.50 mm/s) which was significantly lower 
than the control populations mean Va of 0.53 ± 0.15 mm/s (95% CI 0.52–0.53 mm/s (p < 0.001)).
Overall mean blood volume flow (Q) did not differ significantly between the control and MI groups (153 ± 124 
pl/s (95% CI 147–157 pl/s) vs. 154 ± 125 pl/s (95% CI 149–159 pl/s), p = 0.84). Wall shear rate (WSR) was signifi-
cantly lower in the MI population, compared to the healthy controls (control 162 ± 93  s−1 (95% CI 118–166  s−1) 
vs. MI 145 ± 88  s−1 (95% CI 141–149  s−1), p < 0.001). Table 4 summarises the differences between the two study 
groups.
Microcirculatory parameters were sub-analysed between the two groups based on the four vessel size group-
ings described above. The largest diameter vessels (group 4, > 22 μm) were the most frequently observed vessels 
with vessel frequency decreasing from group 4 down to group 1.
Axial velocity (Va) was lower for the MI patients through all vessel size groups, meeting statistical signifi-
cance for groups 2–4. Blood volume flow (Q) was also lower for MI patients in all vessel size groups and this met 
statistical significance for the most numerically abundant vessels i.e. groups 3 and 4. Wall shear rate (WSR) was 
consistently lower for the MI patients for all vessel groups and met statistical significance for groups 2–4. Table 5 
is a summary of the microcirculatory comparisons for each of the four vessel size groups.
The conjunctival measurements were compared between the STEMI and NSTEMI patient groups. Despite the 
differences in presentation, myocardial biomarkers and prevalence of left ventricular systolic dysfunction there 
were no significant differences between the two groups with respect to any of the conjunctival measurements as 
summarised in Supplementary Table 1.
Within the MI population sub-group analysis of specific comorbidities the only significant difference in 
microcirculatory parameters was a higher Q (181 ± 61 pl/s vs 151 ± 39 pl/s, p = 0.04) in diabetic (DM) patients 
(n = 12) compared to non-diabetics (n = 47) as presented in Fig. 3.
No significant differences were noted for the remainder of the microcirculatory parameters on subgroup 
analysis of smoking st.atus, impaired LV systolic function (LVEF < 50%), systemic HTN and hypercholesterol-
aemia. Supplementary Figure 1a–c illustrate the microcirculatory parameters sub-group analysis.
Discussion
Our study demonstrated differences in conjunctival microcirculatory parameters for a group of high CVD risk 
patients post-MI compared to a group of healthy volunteers. The physiological changes and endothelial dysfunc-
tion, associated with atherosclerosis and CVD, typically manifest earliest in the microvasculature within the 
 body5. The progressive process which leads to myocardial ischaemia is known as the ischaemic  cascade34. This 
process begins with localised metabolic and endothelial function changes in the coronary circulation. Perfusion 
defects typically occur next in this cascade, followed by cardiac myocyte dysfunction and changes in the patient 
ECG which can result in angina or MI.
There was a significant reduction in Va for patients with history of recent acute MI compared to the healthy 
controls, suggestive of endothelial dysfunction and this is consistent with prior findings in patients with other 
forms of  CVD17,18,35. Slower coronary flow has previously been associated with atherosclerosis and increased risk 
of obstructive coronary artery  disease36 and our findings would suggest a possible correlation between diminished 
epicardial blood flow and conjunctival Va. The most pronounced statistical differences for Va between the two 
study groups were observed for vessel size groups 2–4.
Overall blood volume flow (Q) did not differ significantly between the two study groups but was significantly 
lower in the MI group for vessel groups 3 and 4. These were the most numerically abundant vessel groups in the 
study. This may be explained by the distribution of venules and arterioles across the vessel size groupings. Dif-
ferences in conjunctival Q was not reported in other studies of the conjunctival microcirculation in high CVD 
risk patients e.g. ischaemic stroke patients and diabetic  patients17,18.
Table 4.  Summary of conjunctival microcirculatory parameters for all vessel sizes for both populations. Bold 
values are statistically significant (p < 0.05). D diameter, SD standard deviation, Va axial velocity, Q blood 
volume flow, WSR wall shear rate, MI myocardial infarction.
Haemodynamic parameter Controls (n = 56) MI patients (n = 59) p value
D, μm ± SD 21.43 ± 7.57 22.32 ± 7.66  < 0.001
Va, mm/s ± SD 0.53 ± 0.15 0.49 ± 0.17  < 0.001
Q, pl/s ± SD 153 ± 124 154 ± 125 0.84
WSR,  s−1 ± SD 162 ± 93 145 ± 88  < 0.001
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WSR was significantly reduced for the MI patients compared to the healthy controls, and this was consistent 
throughout all the vessel groups. Reduced WSR has previously been reported in patients at risk of  CVD15,18. 
WSR has an important role in endothelial  function37,38 and reduced WSR can lead to abnormal vascular wall 
 remodelling39. Wall shear stress (WSS) is a direct product of WSR and plasma viscosity. Patients suffering type 1 
acute MI have epicardial macrocirculatory  disease24. Microcirculatory dysfunction, in the form of reduced WSS, 
has been reported in the coronary arteries of acute coronary syndrome patients with high-risk  plaques40. Our 
findings would suggest that reduced WSR has a potential role in identifying those patients at high risk of MACE.
To our knowledge, at the time of writing, we are the only group to report findings and differences in conjunc-
tival microcirculatory parameters for MI patients compared to healthy volunteers.
A potential limitation is that we studied the microcirculatory parameters without separating vessels into 
arterioles and venules. Differentiation between venules and arterioles has been reported previously based on the 
manually observed direction of flow within each  vessel10,11. A major limitation of this method though is human 
Table 5.  Comparison of conjunctival microcirculatory parameters based on vessel group. Bold values are 
statistically significant (p < 0.05). D diameter, SD standard deviation, Va axial velocity, Q blood volume flow, 
WSR wall shear rate, MI myocardial infarction.
Haemodynamic parameter Control group (n = 56) MI population (n = 59) p value
Group 1 (< 11 μm) No. vessels 165 No. vessels 178
D, μm ± SD 9.12 ± 1.33 9.04 ± 1.36 0.64
Va, mm/s ± SD 0.49 ± 0.14 0.46 ± 0.15 0.08
Q, pl/s ± SD 26 ± 10 24 ± 10 0.15
WSR,  s−1 ± SD 357 ± 132 339 ± 128 0.22
Group 2 (11–16 μm) No. vessels 325 No. vessels 324
D, μm ± SD 13.55 ± 1.47 13.70 ± 1.35 0.205
Va, mm/s ± SD 0.49 ± 0.14 0.46 ± 0.16 0.02
Q, pl/s ± SD 54 ± 19 52 ± 21 0.13
WSR,  s−1 ± SD 221 ± 70 205 ± 75 0.005
Group 3 (16–22 μm) No. vessels 512 No. vessels 571
D, μm ± SD 19.16 ± 1.78 19.26 ± 1.72 0.382
Va, mm/s ± SD 0.51 ± 0.14 0.47 ± 0.16  < 0.001
Q, pl/s ± SD 105 ± 35 99 ± 39 0.001
WSR,  s−1 ± SD 152 ± 45 140 ± 49  < 0.001
Group 4 (> 22 μm) No. vessels 902 No. vessels 1186
D, μm ± SD 27.81 ± 4.91 28.14 ± 4.93 0.06
Va, mm/s ± SD 0.55 ± 0.16 0.52 ± 0.17  < 0.001
Q, pl/s ± SD 239 ± 129 228 ± 128 0.01
WSR,  s−1 ± SD 111 ± 35 102 ± 37  < 0.001
Figure 3.  Sub-group analysis of MI patients with respect to microvessel blood volume flow (Q). n denotes 
the number of “yes” for each sub-group. DM diabetes mellitus, HTN hypertension, Dyslip. dyslipidaemia, 
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error and the inability to reliably identify branching patterns. Automated differentiation of vessels into venules 
and arterioles would take require extensive technical development and was not possible within the confines of this 
pilot study. Haemoglobin video imaging (HVI) may also have the potential to help assess the conjunctival vessel 
hierarchy and vessel  distribution21 but our methods would require further technical development to allow for 
integration into our model. Vessel differentiation may explain the statistical differences in blood volume flow that 
were only appreciated for group size 3–4 vessels. Another limitation is the inter-visit variability in conjunctival 
measurements. All MI patients and controls were recruited at one time-point. Previous studies have described the 
inter-visit variability of conjunctival measurements in both healthy  controls41 and diabetic retinopathy  patients42. 
The majority of the MI patients had received at least one dose of routinely prescribed medications (ACE inhibi-
tor, beta-blocker) and all MI patients received dual antiplatelet therapy. These medications could contribute to 
the results observed between the two groups but the median time to recruitment post MI was 1 day and the vast 
majority would have only had a one-two doses of these drugs. As anticipated, there was a higher prevalence of 
diabetes mellitus, smoking history, systemic hypertension and dyslipidaemia in the MI group highlighting the 
severe CVD phenotype of MI patients. The subsequent sub-group analysis only demonstrated a significant dif-
ference in microcirculatory parameters for blood volume flow (Q) in patients with or without diabetes mellitus. 
This is a pilot investigation of MI patients conjunctival assessment and conventional sample size estimation was 
not feasible thus our findings are largely exploratory. Finally, vessels of smaller size were less abundant than the 
larger vessels but using our methods we still provided good results representation from the smaller vessel groups.
In conclusion this study using a slit-lamp biomicroscope and iPhone combination found lower axial velocity 
and wall shear rate in acute MI patients compared to healthy controls. In addition for MI patients, blood volume 
flow was lower in larger vessels compared to healthy controls. These results and the application of these methods 
have potential as an adjunct in cardiovascular risk assessment and screening which merit further development 
and study.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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